Literature DB >> 9708926

Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus.

A Giménez1, A Minguela, P Parrilla, J Bermejo, D Pérez, J Molina, A M García, M A Ortiz, R Alvarez, L M de Haro.   

Abstract

BACKGROUND: There is a considerable degree of subjectivity and, therefore, substantial interobserver and intraobserver disagreement in the diagnosis and grading of dysplastic lesions in Barrett's esophagus (BE). The aim of this study was to evaluate the usefulness of DNA flow cytometry and immunohistochemical staining for p53 protein as objective methods to complement the conventional histologic diagnosis of dysplasia in patients with this disease. The most common problems and the possible advantages of using these procedures are analyzed briefly in this article.
METHODS: Formalin fixed, paraffin embedded tissue from 55 patients diagnosed with BE were processed for flow cytometric measurements (ploidy and proliferation index) and p53 immunostaining.
RESULTS: Both the cytometric data and the positivity of staining for p53 revealed a statistically significant increase throughout the following sequence: no dysplasia --> indefinite for dysplasia --> low grade dysplasia --> high grade dysplasia --> adenocarcinoma. There was also a highly significant correlation between the results of the cytometric study and the positivity of staining for p53.
CONCLUSIONS: In the future, the use of this procedure could play an important role in the evaluation of patients with BE. Considering that staining for p53 is technically simple, economical, and quick, and the materials required are available to most pathology laboratories, this method appears to be a firm candidate for application as a biomarker in BE. The authors have shown that it is possible to obtain adequate results for cytometric analysis with small formalin fixed, paraffin embedded biopsies if a strict protocol for the acceptance of tissue samples and/or histograms is observed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708926     DOI: 10.1002/(sici)1097-0142(19980815)83:4<641::aid-cncr3>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

Review 2.  Early events during neoplastic progression in Barrett's esophagus.

Authors:  Brian J Reid
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

3.  Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.

Authors:  B J Reid; L J Prevo; P C Galipeau; C A Sanchez; G Longton; D S Levine; P L Blount; P S Rabinovitch
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

4.  Predicting Neoplastic Progression in Barrett's Esophagus.

Authors:  Jean S Wang; Marcia I Canto
Journal:  Ann Gastroentol Hepatol       Date:  2010-06

5.  Abnormal expression of biomarkers in incompletely ablated Barrett's esophagus.

Authors:  Katerina Dvorak; Lois Ramsey; Claire M Payne; Richard Sampliner; Ronnie Fass; Harris Bernstein; Anil Prasad; Harinder Garewal
Journal:  Ann Surg       Date:  2006-12       Impact factor: 12.969

6.  Dysplasia in Barrett's Esophagus.

Authors:  Marcos Pedrosa
Journal:  Curr Treat Options Gastroenterol       Date:  2001-02

7.  NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.

Authors:  Patricia C Galipeau; Xiaohong Li; Patricia L Blount; Carlo C Maley; Carissa A Sanchez; Robert D Odze; Kamran Ayub; Peter S Rabinovitch; Thomas L Vaughan; Brian J Reid
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

8.  Microsatellite instability in metaplasia-dysplasia-adenocarcinoma sequence of Barrett esophagus: a retrospective study.

Authors:  Pave Markoš; Iva Brčić; Luka Brčić; Jasminka Jakić-Razumović; Roland Pulanić
Journal:  Croat Med J       Date:  2018-06-30       Impact factor: 1.351

Review 9.  Utility of ancillary studies in the diagnosis and risk assessment of Barrett's esophagus and dysplasia.

Authors:  Won-Tak Choi; Gregory Y Lauwers; Elizabeth A Montgomery
Journal:  Mod Pathol       Date:  2022-03-08       Impact factor: 8.209

10.  Persistent or recurrent Barrett's neoplasia after an endoscopic therapy session is associated with DNA content abnormality and can be detected by DNA flow cytometric analysis of paraffin-embedded tissue.

Authors:  Christopher J Bowman; Ruth Zhang; Dana Balitzer; Dongliang Wang; Peter S Rabinovitch; Bence P Kővári; Aras N Mattis; Sanjay Kakar; Gregory Y Lauwers; Won-Tak Choi
Journal:  Mod Pathol       Date:  2021-06-09       Impact factor: 7.842

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.